Nivalis Therapeutics Inc (NVLS) is Downgraded by Robert W. Baird to Neutral, Lowers Price Target to $ 3

Nivalis Therapeutics Inc (NVLS) was Downgraded by Robert W. Baird to ” Neutral” while Lowering the Price Target of the company shares to $ 3 from a previous price target of $29 . Earlier the firm had a rating of “Outperform ” on the company shares. Robert W. Baird advised their investors in a research report released on Nov 29, 2016.

Many Wall Street Analysts have commented on Nivalis Therapeutics Inc. Shares were Downgraded by Stifel on Nov 29, 2016 to ” Hold” and Lowered the Price Target to $ 3.25 from a previous price target of $16 .Nivalis Therapeutics Inc was Downgraded by Raymond James to ” Mkt Perform” on Nov 29, 2016. Raymond James Initiated Nivalis Therapeutics Inc on Sep 13, 2016 to “Outperform”, Price Target of the shares are set at $20.

Nivalis Therapeutics Inc opened for trading at $6.2 and hit $6.37 on the upside on Friday, eventually ending the session at $6.28, with a gain of 0.48% or 0.03 points. The heightened volatility saw the trading volume jump to 9,943 shares. Company has a market cap of $98 M.

In a different news, on Oct 5, 2016, David Malcom Rodman (Exec Vice President and CMO) sold 5,820 shares at $7.96 per share price. According to the SEC, on Jun 17, 2016, Jon Congleton (CEO) purchased 5,000 shares at $3.87 per share price. On Dec 11, 2015, Robert E Conway (director) purchased 10,000 shares at $8.10 per share price, according to the Form-4 filing with the securities and exchange commission.

Nivalis Therapeutics Inc. is a United States-based clinical-stage pharmaceutical company. It is engaged in the discovery development and commercialization of product candidates for patients with cystic fibrosis. The Company has developed a portfolio of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) which is used to increase and prolong cystic fibrosis transmembrane conductance regulator (CFTR) activity and to decrease inflammation. Its drug candidate portfolio consists of various compounds for oral intravenous (IV) or inhaled administration. The Company’s lead clinical candidate is N91115 which is an investigational small molecule that addresses a defect in CFTR resulting from mutations in the CFTR gene. N91115 is designed to stabilize CFTR inside the cell and at the cell surface. N91115 is a CFTR stabilizer that modulates CFTR activity.

Nivalis Therapeutics Inc

Leave a Reply

Nivalis Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nivalis Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.